卡替洛尔

Description

Carteolol · CAS 51781-06-7 · C16H24N2O3. UNII 8NF31401XG. Solubility: 4.21e-01 g/L; LogP: 1.1; LogP: 1.49.

Identification

CAS Registry Number	51781-06-7
PubChem CID	2583
Molecular formula	C16H24N2O3
IUPAC name	5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
UNII (FDA)	8NF31401XG

Computed Descriptors

Molecular Weight	292.37
XLogP3	1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	6
Exact Mass	292.17869263
Monoisotopic Mass	292.17869263
Topological Polar Surface Area	70.6
Heavy Atom Count	21
Formal Charge	0

Physical & Chemical Properties

Solubility	4.21e-01 g/L
LogP	1.1
LogP	1.49

Physical description & handling notes

• Solid

Documented Uses

• For the treatment of intraocular hypertension and chronic open-angle glaucoma
• Breast Feeding; Lactation; Milk, Human; Adrenergic Beta-Antagonists; Antiglaucoma Agents
• Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
• Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
• Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
• Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.

Synonyms

CARTEOLOL; 51781-06-7; Carteololum; 8NF31401XG; 2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-; CHEBI:3437; DTXSID3022746; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinolin-2-one; carteololo; 5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydroquinolin-2-ol; 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2-ol; 5-(3-(tert-butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydroquinolin-2-one; RefChem:58563; DTXCID202746; C07AA15; S01ED05

Frequently Asked Questions

What are the CAS number and molecular formula of Carteolol?

CAS 51781-06-7; molecular formula C16H24N2O3; molecular weight — g/mol.

What other names is Carteolol known by?

CARTEOLOL, 51781-06-7, Carteololum, 8NF31401XG, 2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, CHEBI:3437.

What are the key physical properties of Carteolol?

Solubility: 4.21e-01 g/L; LogP: 1.1; LogP: 1.49.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.